Exclusive: Medivation succumbs to pressure to explore sale - sources
May 11, 2016, 3:07 pm     |   Source: Reuters

U.S. cancer drug maker Medivation Inc has decided to explore a sale following a $9.3 billion acquisition offer from France`s Sanofi SA and interest from other companies, people familiar with the matter said on Monday.

Pfizer Inc and Amgen Inc are among the companies that have signed non-disclosure agreements with Medivation, which allow them to obtain confidential information about the company, the people said.

The move comes less than two weeks after Sanofi made its approach public by publishing a letter to Medivation`s chief executive David Hung that contained details of the offer.

However, there is still no certainty that Sanofi`s rivals will press ahead with bids for Medivation, the people cautioned.

The sources asked not to be identified because the deliberations are confidential. Medivation, Sanofi, Pfizer and Amgen declined to comment.

Medivation said last week that Sanofi`s $52.50 per share cash offer "substantially undervalues the company, its leading oncology franchise, and innovative late-stage pipeline." Medivation shares traded on Monday at $62.54, and were trading at around $62 in morning trading in New York on Tuesday.

Sanofi has said it is willing to raise its offer as long as Medivation engages in negotiations, and has threatened to go directly to shareholders to oust its board if it does not.



Sanofi, which is being advised by Morgan Stanley, has a track record of pushing through unsolicited deals, after buying Genzyme for $20 billion in 2011.

A sale of Medivation would mark a bittersweet moment for Hung, who founded the company in 2003. In 13 years, he built Medivation from a penny stock peddling a 20-year-old Russian treatment for hay fever into a $10 billion market capitalization oncology company.

In the process, he overcame numerous obstacles, including the failure of Alzheimer`s treatment Dimebon, which used to be sold as an antihistamine in Russia. In 2009, Hung took a bet on a chemical compound called MDV3100, which was developed at the University of California, Los Angeles. In partnership with Japan`s Astellas Pharma Inc, Medivation turned MDV3100 into a nearly $2 billion dollar prostate cancer drug called Xtandi.

Xtandi`s successful progression from early stage experiments to full blown regulatory approval was one of the fastest in biopharmaceutical history, taking only seven years.

At times, Hung resorted to unconventional methods to finance Medivation`s research, including tapping the public markets through a 2004 reverse merger with a shell company, which he used to raise $12 million in public capital.

Prior to joining Medivation, Hung was already an experienced life sciences executive, having previously led a medical device company, Pro-Duct Health, to a more than $167 million sale in 2001.



Comments

m1.png m2.png m3.png m4.png m5.png
f1.png f2.png f3.png f4.png f5.png
+ =
Latest Videos
VIDEO: The Biology of Bliss and the Human OS - Jamie Wheal
Terror and Tourism: Changing the Travel Landscape
Earth In 2050 - HD Documentary 2015
The drive for gender equality in corporate Japan
Plane touches down then aborts during storm (VIDEO)
The Fermi Paradox II — Solutions and Ideas – Where Are All The Aliens (VIDEO)
Money Survival Tips for Millennials (VIDEO)
Lightning strike explodes a tree (VIDEO)
Latest Photos
best cities for small businesses
Best Jobs in America (PHOTOS)
Inside the coolest private jets (PHOTOS)
The best hotel club floors in the world
Winning Images from the 2015 National Geographic Traveler Photo Contest
PHOTOS: Raging Wildfires Prompt Major Evacuation
Amazing Geometry Cities from air - Photos
Photos Bangkok Get snow - Opens Snow Village